Statistiche di base
| CIK | 1538927 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Forma Therapeutics Holdings Inc
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 14, 2023 |
FMTX / Forma Therapeutics Holdings Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39333 Forma Therapeutics Holdings, Inc. (Exact name of registrant as spe |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 As filed with the Securities and Exchange Commission on October 14, 2022 No. 333-239369 No. 333-254872 No. 333-263206 No. 333-266601 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-239369 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-254872 Post-Effective Amendment No. 1 to |
|
| October 14, 2022 |
FMTX / Forma Therapeutics Holdings Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* FORMA THERAPEUTICS HOLDING, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34633R104 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 POS AM As filed with the Securities and Exchange Commission on October 14, 2022 Registration No. |
|
| October 14, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Forma Therapeutics Holdings, Inc. |
|
| October 14, 2022 |
Press Release issued by Parent, dated October 14, 2022, announcing the expiration of the Offer. EX-99.(A)(5)(C) Exhibit (a)(5)(c) Novo Nordisk announces the completion of the Forma Therapeutics acquisition Bagsværd, Denmark, 14 October 2022 – Novo Nordisk announced today, that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Forma, Novo Nordisk has today acquired a |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 As filed with the Securities and Exchange Commission on October 14, 2022 No. 333-239369 No. 333-254872 No. 333-263206 No. 333-266601 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-239369 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-254872 Post-Effective Amendment No. 1 to |
|
| October 14, 2022 |
Third Amended and Restated Certificate of Incorporation, dated October 14, 2022. EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. October 14, 2022 FIRST: The name of the corporation is Forma Therapeutics Holdings, Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 198 |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 As filed with the Securities and Exchange Commission on October 14, 2022 No. 333-239369 No. 333-254872 No. 333-263206 No. 333-266601 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-239369 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-254872 Post-Effective Amendment No. 1 to |
|
| October 14, 2022 |
Second Amended and Restated By-Laws, dated October 14, 2022. EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF FORMA THERAPEUTICS HOLDINGS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaw |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| October 14, 2022 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) FORMA THERAPEUTICS HOLDINGS, INC. (Name of Subject Company (Issuer)) NNUS NEW DEV, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stoc |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 As filed with the Securities and Exchange Commission on October 14, 2022 No. 333-239369 No. 333-254872 No. 333-263206 No. 333-266601 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-239369 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT No. 333-254872 Post-Effective Amendment No. 1 to |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) FORMA THERAPEUTICS HOLDINGS, INC. (Name of Subject Company (Issuer)) NNUS NEW DEV, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Val |
|
| October 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Forma Therapeutics Holdings, Inc. |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) FORMA THERAPEUTICS HOLDINGS, INC. (Name of Subject Company (Issuer)) NNUS NEW DEV, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Val |
|
| September 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Forma Therapeutics Holdings, Inc. |
|
| September 15, 2022 |
Exhibit (a)(1)(C) Offer to Purchase For Cash All Outstanding Shares of Common Stock of FORMA THERAPEUTICS HOLDINGS, INC. |
|
| September 15, 2022 |
Forma Therapeutics Holdings, LLC Equity Incentive Plan (Amended and Restated) Exhibit (e)(6) Forma Therapeutics Holdings, LLC Equity Incentive Plan (Amended and Restated) 1. |
|
| September 15, 2022 |
MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (d)(3) MUTUAL CONFIDENTIALITY AGREEMENT THIS MUTUAL CONFIDENTIALITY AGREEMENT (this ?Agreement?) is entered into as of January 18, 2022 (the ?Effective Date?) and governs the disclosure of information by and between Novo Nordisk HealthCare AG, having its principal office at The Circle 32, CH- 8058 Zurich, Switzerland (?Novo?), and Forma Therapeutics, Inc. |
|
| September 15, 2022 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of FORMA THERAPEUTICS HOLDINGS, INC. |
|
| September 15, 2022 |
Exhibit (a)(1)(D) Offer to Purchase to For Cash All Outstanding Shares of Common Stock of FORMA THERAPEUTICS HOLDINGS, INC. |
|
| September 15, 2022 |
Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of FORMA THERAPEUTICS HOLDINGS, INC. |
|
| September 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Forma Therapeutics Holdings, Inc. |
|
| September 15, 2022 |
Exhibit (d)(4) August 17, 2022 CONFIDENTIAL Forma Therapeutics Holdings, Inc. 300 North Beacon Street, Suite 501 Watertown, Massachusetts 02472 Re: Exclusivity Agreement Ladies and Gentlemen: Novo Nordisk Health Care AG (?Buyer?) and Forma Therapeutics Holdings, Inc. (the ?Company?) are discussing a possible acquisition of the Company by Buyer or its affiliates (the ?Potential Transaction?). To in |
|
| September 15, 2022 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| September 15, 2022 |
[Remainder of page intentionally blank] Exhibit (d)(2) CONFIDENTIAL Forma Therapeutics Holdings, Inc. 300 North Beacon Street, Suite 501 Watertown, Massachusetts 02472 June 27, 2022 Novo Nordisk Health Care AG The Circle 32/38 CH-8058 Zurich, Switzerland Re: Confidentiality Agreement Novo Nordisk Health Care AG (referred to herein as ?you or your?) has requested certain Evaluation Material (as defined below) from Forma Therapeutics Hold |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 FORMA THERAPEUTICS HOLDINGS, INC. (Name of Subject Company (Issuer)) NNUS NEW DEV, INC. an indirect wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Shar |
|
| September 15, 2022 |
SC 14D9 1 d394912dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Persons Filing Statement) Common Stock, |
|
| September 2, 2022 |
FMTX / Forma Therapeutics Holdings Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* FORMA THERAPEUTICS HOLDING, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34633R104 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit |
|
| September 1, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG NOVO NORDISK A/S, NNUS NEW DEV, INC. and FORMA THERAPEUTICS HOLDINGS, INC. Dated as of August 31, 2022 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 Section 1.1. Definitions 2 ARTICLE 2 THE OFFER 15 Section 2.1. Tender Offer 15 Section 2.2. Actions of Parent and Merger Sub 17 Section 2.3. Actions of the Company 18 ARTICLE 3 THE MERGER; EFFECTIVE TI |
|
| September 1, 2022 |
Exhibit 99.2 Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders Bagsv?rd, Denmark and Watertown, Mass, US September 1, 2022 ? Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cas |
|
| September 1, 2022 |
Exhibit 99.5 TO: Key shareholders, sell-side analysts Subject: Forma Therapeutics to Be Acquired by Novo Nordisk [NAME], We just announced that Forma Therapeutics (NASDAQ: FMTX) has entered into an agreement to be acquired by Novo Nordisk for $20 per share in cash. The purchase price represents a total equity value of $1.1 billion and a 92% premium to the volume-weighted average price per share ov |
|
| September 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) ( |
|
| September 1, 2022 |
Exhibit 99.6 Dear [NAME], I am reaching out to share some important news about Forma Therapeutics. Today, Forma announced that it has accepted an offer to be acquired by Novo Nordisk, a global healthcare company. This is an exciting milestone for our Company that we believe will drive our work faster and farther and benefit the patient community we serve. For the full announcement, you can read th |
|
| September 1, 2022 |
Exhibit 99.1 Hello Forma Colleagues ? Moments ago, we announced that Forma Therapeutics has accepted an offer to be acquired by Novo Nordisk, a global healthcare company, for $1.1 billion, or $20 per share, in cash. You can read the full press release here. Novo Nordisk has a century-long track record of leadership in hemophilia and other rare and orphan diseases, as well as expertise in sickle ce |
|
| September 1, 2022 |
Exhibit 99.2: Forma Employee Q&A, first used on September 1, 2022 Exhibit 99.2 Employee FAQ 1. What was announced? ? Forma has agreed to be acquired by Novo Nordisk, a global healthcare company whose purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. ? This is an important milestone for our company that we believe will enable us to bring etavopivat to people around the world mo |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Name of Subject Company) Forma Therapeutics Holdings, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 34633R104 (C |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 FORMA THERAPEUTICS HOLDINGS, INC. (Name of Subject Company (Issuer)) NNUS NEW DEV, INC. a wholly owned subsidiary of NOVO NORDISK A/S (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.001 Per Share (Title o |
|
| September 1, 2022 |
1 September 2022 Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders Bagsv?rd, Denmark and Watertown, Mass, US , 01 September 2022 ? Novo Nordisk and Forma Therapeutics, Holdings Inc. |
|
| September 1, 2022 |
Exhibit 99.4: Announcements by Forma via Twitter on September 1, 2022 Exhibit 99.4 On September 1, 2022, Forma Therapeutics, Inc. (?Forma?) made the following announcements via Twitter regarding the planned cash tender offer (the ?Offer?) by NNUS New Dev, Inc., a Delaware corporation (?Purchaser?) and a wholly owned indirect subsidiary of Novo Nordisk A/S, a Danish aktieselskab (?Novo Nordisk?), to acquire all of the issued and outstanding shares of the common stock |
|
| September 1, 2022 |
Exhibit 99.7 EMAIL COMMUNICATION TO EMPLOYEES ON EQUITY AND CIC RESOURCES Name: XXXXX As communicated at today?s town hall, in the near term, we hope to provide additional clarity on what the Novo Nordisk acquisition may mean for each of you. In the meantime, we wanted to ensure you knew that employees will be eligible for a change in control (CIC) severance package which provides for equity accel |
|
| September 1, 2022 |
Exhibit 99.2 Social Media Posts in connection with the Announcement of Novo Nordisk?s Intent to Acquire Forma Therapeutics Novo Nordisk Tweet (@novonordisk), September 1, 2022 ? https://twitter.com/novonordisk/status/1565310296322973697?s=20&t=l1nCG-g2Fhvgoj8UX-5YWw Copy: #PRESS Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders Link to: |
|
| September 1, 2022 |
Exhibit 99.3: Announcements by Forma and the Forma’s management via LinkedIn on September 1, 2022 Exhibit 99.3 On September 1, 2022, Forma Therapeutics, Inc. (?Forma?) and its Chief Executive Officer Frank D. Lee made the following announcements via LinkedIn regarding the planned cash tender offer (the ?Offer?) by NNUS New Dev, Inc., a Delaware corporation (?Purchaser?) and a wholly owned indirect subsidiary of Novo Nordisk A/S, a Danish aktieselskab (?Novo Nordisk?), to acquire all of the iss |
|
| September 1, 2022 |
Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this ?Agreement?), dated as of August 31, 2022, is entered into by and among Novo Nordisk A/S, a Danish aktieselskab (?Parent?), NNUS New Dev, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (?Merger Sub?), and each of the persons set forth on Schedule A hereto (each, a ?Stockholder? and tog |
|
| August 5, 2022 |
Exhibit 99.1 FORMA THERAPEUTICS HOLDINGS, INC. INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT Name of Optionee: Agustin Melian No. of Option Shares: 118,000 Option Exercise Price per Share: $8.20 Grant Date: July 11, 2022 Vesting Commencement Date: July 11, 2022 Expiration Date: July 10, 2032 Forma Therapeutics Holdings, Inc. (the “Company”) hereby grants to the Optionee named above an option (th |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 5, 2022 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No. |
|
| August 5, 2022 |
Exhibit 99.3 FORMA THERAPEUTICS HOLDINGS, INC. INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT Name of Optionee: Linea Aspesi No. of Option Shares: 59,000 Option Exercise Price per Share: $8.20 Grant Date: July 11, 2022 Vesting Commencement Date: July 11, 2022 Expiration Date: July 10, 2032 Forma Therapeutics Holdings, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “ |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (C |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| August 5, 2022 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 FORMA THERAPEUTICS HOLDINGS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high- caliber director |
|
| August 5, 2022 |
EX-FILING FEES 8 d357710dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Forma Therapeutics Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price |
|
| August 5, 2022 |
Exhibit 99.4 FORMA THERAPEUTICS HOLDINGS, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT Name of Grantee: Linea Aspesi No. of Restricted Stock Units: 39,000 Grant Date: July 11, 2022 Vesting Commencement Date: July 11, 2022 Forma Therapeutics Holdings, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Res |
|
| August 5, 2022 |
EX-99.2 5 d357710dex992.htm EX-99.2 Exhibit 99.2 FORMA THERAPEUTICS HOLDINGS, INC. INDUCEMENT RESTRICTED STOCK UNIT AGREEMENT Name of Grantee: Agustin Melian No. of Restricted Stock Units: 79,000 Grant Date: July 11, 2022 Vesting Commencement Date: July 11, 2022 Forma Therapeutics Holdings, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award” |
|
| August 5, 2022 |
EX-99.1 2 fmtx-ex991.htm EX-99.1 Exhibit 99.1 Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmac |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Co |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Com |
|
| June 3, 2022 |
FMTX / Forma Therapeutics Holdings Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 26, 2022 |
EX-99.1 2 d530777dex991.htm EX-99.1 Exhibit 99.1 Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day Expanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 t |
|
| May 26, 2022 |
EX-99.2 3 d530777dex992.htm EX-99.2 Research and Development Day May 26, 2022 8:00–10:00 a.m. EDT Exhibit 99.2 Legal Disclaimer This Presentation contains forward-looking statements and information of Forma Therapeutics Holdings, Inc. (“we,” “us,” “our,” “Forma” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our current and future prospects |
|
| May 26, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Com |
|
| May 6, 2022 |
Exhibit 99.1 Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Clinical programs advancing in rare hematologic diseases and cancers May 26 R&D Day to focus on research pipeline strategy and expanded development programs Cash balance of $441.3 million positions company with runway through the third quarter of 2024 WATERTOWN, Mass. – May. 6, 2022 – Forma Th |
|
| May 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Comm |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| April 27, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Forma Therapeutics Holdings, Inc. |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 2, 2022 As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
EX-99.1 2 fmtx-ex991.htm EX-99.1 Exhibit 99.1 Forma Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Update Clinical stage programs focused on rare hematologic diseases and cancers Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/I |
|
| March 1, 2022 |
FORMA THERAPEUTICS HOLDINGS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EX-10.3 2 fmtx-ex103.htm EX-10.3 Exhibit 10.3 FORMA THERAPEUTICS HOLDINGS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-t |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39333 Forma Therapeu |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Co |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Forma Therapeutics Holdings, Inc. |
|
| March 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
EX-10.13 3 fmtx-ex1013.htm EX-10.13 Execution Version Exhibit 10.13 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made as of this 23 day of November, 2021 (the “Effective Date”), between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and FORMA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: The specific building in the Project located at 321 |
|
| February 14, 2022 |
FMTX / Forma Therapeutics Holdings Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34633R104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 11, 2022 |
EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Forma Therapeutics Holdings, Inc., a Delaware corporation, and further |
|
| February 11, 2022 |
FMTX / Forma Therapeutics Holdings Inc / Novartis Bioventures Ltd - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
EX-99.2 3 d309389dex992.htm EX-99.2 Exhibit 99.2 Power of Attorney The undersigned, LILLY VENTURES FUND I LLC, a Delaware limited liability company (the “Company”), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on its be |
|
| February 10, 2022 |
FMTX / Forma Therapeutics Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Forma Therapeutics Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 34633R104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1 |
|
| February 10, 2022 |
Exhibit 99.3 Power of Attorney The undersigned, ELI LILLY AND COMPANY, a corporation duly organized under the laws of the State of Indiana, United States (the ?Company?), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on |
|
| February 10, 2022 |
EX-99.1 2 d309389dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement IN ACCORDANCE WITH Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Shares, par value $0.001 per share, of Forma Therapeutics Holdings, Inc., a |
|
| February 10, 2022 |
FMTX / Forma Therapeutics Holdings Inc / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34633R104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| December 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| December 16, 2021 |
EX-99.1 2 d257303dex991.htm EX-99.1 Exhibit 99.1 Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia First Phase 2 combination trial results presented in oral session at 2021 ASH Annual Meeting Olutasidenib with azacitidine well tolerated with a safety profile largely consistent with olutas |
|
| December 13, 2021 |
EX-99.1 2 d231942dex991.htm EX-99.1 Exhibit 99.1 Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions Etavopivat was well tolerated with a safety profile consistent with underlying sickle cell disease Clini |
|
| December 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| December 13, 2021 |
ASH Investor Briefing December 13, 2021 Exhibit 99.2 Legal Disclaimer This Presentation contains forward-looking statements and information of Forma Therapeutics Holdings, Inc. (?we,? ?us,? ?our,? ?Forma? or the ?Company?) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our current and future prospects and our operations and financial results, which are based |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| November 12, 2021 |
Exhibit 99.1 Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results to be presented at American Society of Hematology (ASH) Annual Meeting Decem |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| October 28, 2021 |
FMTX / Forma Therapeutics Holdings Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 34633R104 (CUSIP Nu |
|
| October 7, 2021 |
Exhibit 99.1 Forma Therapeutics? FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer Initial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients Adaptive trial design intended to efficiently expl |
|
| October 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) ( |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| August 13, 2021 |
Exhibit 99.1 Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Significant progress achieved with pipeline focused on rare hematologic diseases and cancers Positive Phase 1 results in patients with sickle cell disease (SCD) presented at European Hematology Association (EHA) Virtual Congress supporting etavopivat?s potential to significantly impact RBC he |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) ( |
|
| July 26, 2021 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.2 FORMA THERAPEUTICS HOLDINGS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee?s |
|
| July 26, 2021 |
Exhibit 1.2 FORMA THERAPEUTICS HOLDINGS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT July 26, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Forma Therapeutics Holdings, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1. I |
|
| July 26, 2021 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.3 FORMA THERAPEUTICS HOLDINGS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trus |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 26, 2021 Registration No. |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Co |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Co |
|
| June 14, 2021 |
Exhibit 99.1 Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer WATERTOWN, Mass. – June 14, 2021 – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice p |
|
| June 11, 2021 |
European Hematology Association INVESTOR PRESENTATION JUNE 11, 2021 Exhibit 99.2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the company?s beliefs and expectations regarding its: business plans and objectives; futu |
|
| June 11, 2021 |
Exhibit 99.1 Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress Clinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease Initial results from an open-label extension c |
|
| June 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Co |
|
| May 14, 2021 |
Exhibit 99.1 Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Development pipeline progressing to key upcoming clinical milestones Multiple-ascending dose (MAD) cohorts of FT-4202 Phase 1 trial in sickle cell disease completed; hemoglobin increase ? 1 g/dL in approximately 71% of patients and improved hematologic and hemolytic markers consistent with imp |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (Com |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| April 21, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted b |
|
| March 30, 2021 |
Exhibit 99.2 Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called The Hibiscus Study Blinded data from the 600 mg dose cohort support the doses (400 mg v 200 mg v placebo) being evaluated in the Hibiscus Study currently enrolling people living with sickle cell disease (SCD) Doubling t |
|
| March 30, 2021 |
As filed with the Securities and Exchange Commission on March 30, 2021 Registration No. |
|
| March 30, 2021 |
Exhibit 4.4 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of Forma Therapeutics Holdings, Inc. (“Forma”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Second A |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) (C |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39333 Forma Therapeu |
|
| March 30, 2021 |
Exhibit 99.1 Forma Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Strong organizational foundation laid in 2020; continued pipeline execution amid the COVID-19 and raised gross capital of $595.1 million Key pipeline achievements include proof of concept for FT-4202 in sickle cell disease; successful interim analysis of registrational Phase 2 t |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation or organizat |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34633R104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 34633R104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 1, 2021 |
EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Forma Therapeutics Holdings, Inc., a Delaware corporation, and further |
|
| February 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 1, 2021 |
EXHIBIT 99.2 POWER OF ATTORNEY We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Bart Dzikowski, Anja Koenig, Stephan Sandmeier, Florian Muellershausen, Beat Steffen, Marc Ceulemans and Marianne Uteng and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our |
|
| February 1, 2021 |
Evidence of Signature Authority EX-99.1 2 tm214797d3ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 EVIDENCE OF SIGNATURE AUTHORITY Excerpt from Commercial Register of Novartis AG Identification number Legal status Entry Cancelled Carried CH-270.3.002.061-2 from: CH-270.3.002.061-2/a 1 CHE-103.867.266 Limited or Corporation 01.03.1996 on: All data In Ca Business name Ref Legal seat 1 Novartis AG 1 Basel 1 (Novartis SA) (Novartis Inc.) CHE- |
|
| January 7, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporatio |
|
| December 11, 2020 |
424B4 Table of Contents File pursuant to Rule 424(b)(4) Registration No. 333-251198 PROSPECTUS 5,300,000 Shares Common Stock We are offering 5,300,000 shares of common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “FMTX.” The last reported sale price of our common stock on The Nasdaq Global Market on December 10, 2020 was $45.50 per share. We are an “emerging growt |
|
| December 10, 2020 |
As filed with the Securities and Exchange Commission on December 10, 2020. As filed with the Securities and Exchange Commission on December 10, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Forma Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 37-1657129 (State or other jurisdiction of incorporation or org |
|
| December 8, 2020 |
VIA EDGAR December 8, 2020 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| December 8, 2020 |
[Remainder of page intentionally left blank] Jefferies LLC 520 Madison Avenue New York, New York 10022 SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 December 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 8, 2020 |
Form S-1 (File No. 333-251198) S-1 Table of Contents As filed with the Securities and Exchange Commission on December 8, 2020. |
|
| December 8, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [●] Shares of Common Stock Forma Therapeutics Holdings, Inc. UNDERWRITING AGREEMENT [●], 2020 JEFFERIES LLC SVB LEERINK LLC CREDIT SUISSE SECURITIES (USA) LLC As Representatives of the several underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 and c/o CREDIT SUISSE SECURITIES ( |
|
| November 13, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 13, 2020. |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporation) |
|
| November 12, 2020 |
Exhibit 99.1 Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Strong pipeline progress amid challenging COVID-19 environment Oral presentation of MAD1 results at upcoming 2020 ASH Virtual Annual Meeting from the randomized, placebo-controlled multi-center Phase 1 trial evaluating FT-4202 in people with sickle cell disease MAD2 cohort of the Phase 1 trial |
|
| November 12, 2020 |
Exhibit 10.3 FORMA THERAPEUTICS HOLDINGS, INC. Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employee |
|
| November 12, 2020 |
Exhibit 10.2 Execution Version LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made as of this 14th day of September, 2020 (the “Effective Date”), between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and FORMA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: The specific building in the Project commonly known as Building 39, located at 300 No |
|
| November 12, 2020 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this “Sixth Amendment”) is made as of September 14, 2020, by and between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and FORMA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A.Landlord and Tenant are parties to that certain Lease Agreement dated as of May 20, 2011, as amended b |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| September 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39333 37-1657129 (State or other jurisdiction of incorporat |
|
| September 9, 2020 |
Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors EX-99.1 Exhibit 99.1 Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors WATERTOWN, Mass. – Sept. 9, 2020 – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of industry veteran Thomas G. Wiggans to its board of directors. Mr. Wiggans has le |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38944 37-1657129 (State or other jurisdiction of incorporatio |
|
| August 13, 2020 |
EX-99.1 Exhibit 99.1 Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Completed upsized IPO in June 2020 raising $319.3 million in gross proceeds Advanced pipeline focused on rare hematologic diseases and cancers, including reporting favorable single-dose data for FT-4202 in sickle cell disease (SCD) from a randomized, multi-center, placebo-controlled P |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39333 Forma Therapeutics Holdings, Inc. |
|
| July 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38944 37-1657129 (State or other jurisdiction of incorporation) |
|
| July 30, 2020 |
EX-99.1 Exhibit 99.1 Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors WATERTOWN, Mass. – July 30, 2020 – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Wayne A.I. Frederick, M.D., has been elected to serve on the comp |
|
| July 30, 2020 |
EX-99.1 Exhibit 99.1 Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors WATERTOWN, Mass. – July 30, 2020 – Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Wayne A.I. Frederick, M.D., has been elected to serve on the comp |
|
| July 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38944 37-1657129 (State or other jurisdiction of incorporation) |
|
| July 6, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 6, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the |
|
| July 6, 2020 |
FMTX / Forma Therapeutics Holdings, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forma Therapeutics Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34633R104 (CUSIP Number) June 23, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 25, 2020 |
Exhibit 1 Joint Filing Agreement by and among the Reporting Persons. CUSIP No. 34633R104 13D Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of June 25, 2020, is by and among RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D |
|
| June 25, 2020 |
FMTX / Forma Therapeutics Holdings, Inc. / RA Capital Management, LLC - SC 13D Activist Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| June 23, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FORMA THERAPEUTICS HOLDINGS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, dat |
|
| June 23, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 23, 2020 Registration No. |
|
| June 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 FORMA THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38944 37-1657129 (State or other jurisdiction of incorporation) |
|
| June 23, 2020 |
EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. Forma Therapeutics Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Forma Therapeutics Holdings, Inc. The date of the filing of its original Certificate of Inc |
|
| June 22, 2020 |
13,882,352 Shares Common Stock 424B4 Table of Contents File pursuant to rule 424(b)(4) Registration No. 333-238783 PROSPECTUS 13,882,352 Shares Common Stock We are offering 13,882,352 shares of common stock. This is our initial public offering of our common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $20.00 per share. Our common stock has been approved for |
|
| June 18, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on June 18, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Forma Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 37-1657129 (State or other jurisdiction of incorporation or |
|
| June 16, 2020 |
CORRESP Jefferies LLC 520 Madison Avenue New York, New York 10022 SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 June 16, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 16, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Forma Therapeutics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 37-1657129 (State of incorporation or organization) (I.R.S. Employer Identification No.) 500 |
|
| June 16, 2020 |
CORRESP VIA EDGAR June 16, 2020 Office of Healthcare and Insurance Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| June 15, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 15, 2020. |
|
| June 15, 2020 |
EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. WA |
|
| June 15, 2020 |
EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. Forma Therapeutics Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Forma Therapeutics Holdings, Inc. The date of the filing of its original Certificate of Inc |
|
| June 15, 2020 |
EX-10.2 Exhibit 10.2 FORMA THERAPEUTICS HOLDINGS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Forma Therapeutics Holdings, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Forma Therapeutics Holdin |
|
| June 15, 2020 |
EX-10.5 Exhibit 10.5 FORMA THERAPEUTICS HOLDINGS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Forma Therapeutics Holdings, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Forma Therapeutics Holdings, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, p |
|
| June 15, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF FORMA THERAPEUTICS HOLDINGS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, dat |
|
| June 15, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [●] Shares Forma Therapeutics Holdings, Inc. UNDERWRITING AGREEMENT [Date] JEFFERIES LLC SVB LEERINK LLC CREDIT SUISSE SECURITIES (USA) LLC As Representatives of the several underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o SVB LEERINK LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 and c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Mad |
|
| June 15, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Forma Therapeutics Holdings, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES |
|
| June 15, 2020 |
Non-Employee Director Compensation Policy. EX-10.3 Exhibit 10.3 FORMA THERAPEUTICS HOLDINGS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not |
|
| June 15, 2020 |
EX-10.4 Exhibit 10.4 FORMA THERAPEUTICS HOLDINGS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Forma Therapeutics Holdings, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to |
|
| June 15, 2020 |
EX-10.6 EXHIBIT 10.6 FORMA THERAPEUTICS HOLDINGS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indem |
|
| June 15, 2020 |
EX-10.11 Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made between FORMA Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (th |
|
| June 15, 2020 |
EX-4.2 Exhibit 4.2 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Forma Therapeutics Holdings, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certifi |
|
| May 29, 2020 |
EX-10.8 Exhibit 10.8 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 6th day of October, 2008 (the “Effective Date”), by and between STEVEN TREGAY (the “Employee”) and FORMA THERAPEUTICS, INC., a Delaware corporation duly organized under law and having a usual place of business at 790 Memorial Drive, Cambridge, MA 02139 (the “Company”). RECITALS |
|
| May 29, 2020 |
Employment Agreement between the Registrant and Robert T. Sarisky, dated August 15, 2012. EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 15th day of August, 2012 (the “Effective Date”) by and between ROBERT T. SARISKY (the “Employee”) and FORMA THERAPEUTICS, INC., a Delaware corporation duly organized under law and having a usual place of business at 500 Arsenal Street, Suite 100, Watertown, MA 02472 (the “Compan |
|
| May 29, 2020 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. [***] LICENSE AGREEMENT by and among FORMA THERAPEUTICS HOLDINGS, LLC a limited liability company formed under the la |
|
| May 29, 2020 |
EX-10.15 Exhibit 10.15 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ASSET PURCHASE AGREEMENT BY AND BETWEEN INTEGRAL HEALTH, INC. (“PURCHASER”); FORMA THERAPEUTICS, INC. (“SELLER”); and |
|
| May 29, 2020 |
CORRESP (Cheap Stock Letter) Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw. |
|
| May 29, 2020 |
EX-4.1 Exhibit 4.1 Execution Version THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 18, 2019, by and among Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on Exhibit A hereto, each of which (together with any transferee of Preferred S |
|
| May 29, 2020 |
CORRESP (SEC Response Letter) Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw. |
|
| May 29, 2020 |
By-laws of the Registrant, as currently in effect. EX-3.3 Exhibit 3.3 BY-LAWS OF FORMA THERAPEUTICS HOLDINGS, INC. A DELAWARE CORPORATION Dated: October 2, 2019 TABLE OF CONTENTS ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings 1 Section 2. Annual Meeting 1 Section 3. Special Meetings 1 Section 4. Notice of Meetings 2 Section 5. Voting List 2 Section 6. Quorum 2 Section 7. Adjournments 2 Section 8. Action at Meetings 3 Section 9. |
|
| May 29, 2020 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Forma Securities Corporation Massachusetts Forma Therapeutics, Inc. Delaware |
|
| May 29, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on May 29, 2020. |
|
| May 29, 2020 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Forma Therapeutics Holdings, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES |
|
| May 29, 2020 |
EX-10.7 Exhibit 10.7 Net/Gross Multi-Tenant Office/Laboratory 500 Arsenal St., Watertown, MA Forma Therapeutics - Page 1 LEASE AGREEMENT This LEASE AGREEMENT (this “Lease”) is made as of this 20th day of May, 2011, between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and FORMA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). BASIC LEASE PROVISIONS Address: |
|
| May 29, 2020 |
EX-10.12 Exhibit 10.12 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Contract No. 43041385 COLLABORATION AND LICENSE AGREEMENT’ This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) |
|
| May 29, 2020 |
EX-10.10 Exhibit 10.10 CONFIDENTIAL October 31, 2019 (as revised February 25, 2020) Dr. Steven Tregay Re: Separation and Release Agreement Dear Steve: This letter constitutes the separation agreement (the “Agreement”) that FORMA Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. As you know, the Company has previously offered you (in June 2019 and in Octobe |
|
| May 29, 2020 |
EX-10.14 Exhibit 10.14 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. [***] LICENSE AGREEMENT by and among FORMA THERAPEUTICS HOLDINGS, LLC a limited liability company formed under the la |
|
| May 29, 2020 |
EX-10.1 Exhibit 10.1 FORMA THERAPEUTICS HOLDINGS, INC. 2019 STOCK INCENTIVE PLAN 1. Purpose and Eligibility. The purpose of this 2019 Stock Incentive Plan (the “Plan”) of Forma Therapeutics Holdings, Inc. (the “Company”) is to provide stock options and other equity interests (including restricted stock, restricted stock units and other stock-based interests) in the Company (each an “Award”) to emp |
|
| May 15, 2020 |
EX-10.8 Exhibit 10.8 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 6th day of October, 2008 (the “Effective Date”), by and between STEVEN TREGAY (the “Employee”) and FORMA THERAPEUTICS, INC., a Delaware corporation duly organized under law and having a usual place of business at 790 Memorial Drive, Cambridge, MA 02139 (the “Company”). RECITALS |
|
| May 15, 2020 |
October 31, 2019 (as revised February 25, 2020) EX-10.10 Exhibit 10.10 CONFIDENTIAL October 31, 2019 (as revised February 25, 2020) Dr. Steven Tregay Re: Separation and Release Agreement Dear Steve: This letter constitutes the separation agreement (the “Agreement”) that FORMA Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. As you know, the Company has previously offered you (in June 2019 and in Octobe |
|
| May 15, 2020 |
EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 15th day of August, 2012 (the “Effective Date”) by and between ROBERT T. SARISKY (the “Employee”) and FORMA THERAPEUTICS, INC., a Delaware corporation duly organized under law and having a usual place of business at 500 Arsenal Street, Suite 100, Watertown, MA 02472 (the “Compan |
|
| May 15, 2020 |
DRSLTR FOIA CONFIDENTIAL TREATMENT REQUESTED May 15, 2020 Irene Paik Christie Wong Angela Connell Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| May 15, 2020 |
EX-10.7 Exhibit 10.7 Net/Gross Multi-Tenant Office/Laboratory 500 Arsenal St., Watertown, MA Forma Therapeutics - Page 1 LEASE AGREEMENT This LEASE AGREEMENT (this “Lease”) is made as of this 20th day of May, 2011, between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and FORMA THERAPEUTICS, INC., a Delaware corporation (“Tenant”). BASIC LEASE PROVISIONS Address: |
|
| May 15, 2020 |
EX-10.15 Exhibit 10.15 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ASSET PURCHASE AGREEMENT BY AND BETWEEN INTEGRAL HEALTH, INC. (“PURCHASER”); FORMA THERAPEUTICS, INC. (“SELLER”); and |
|
| May 15, 2020 |
DRS/A Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on May 15, 2020 as Amendment No. |
|
| May 6, 2020 |
EX-10.14 Exhibit 10.14 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. [***] LICENSE AGREEMENT by and among FORMA THERAPEUTICS HOLDINGS, LLC a limited liability company formed under the la |
|
| May 6, 2020 |
Contract No. 43041385 COLLABORATION AND LICENSE AGREEMENT’ EX-10.12 Exhibit 10.12 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Contract No. 43041385 COLLABORATION AND LICENSE AGREEMENT’ This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) |
|
| May 6, 2020 |
DRS/A FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on May 6, 2020. |
|
| May 6, 2020 |
EX-10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. [***] LICENSE AGREEMENT by and among FORMA THERAPEUTICS HOLDINGS, LLC a limited liability company formed under the la |
|
| April 8, 2020 |
DRS Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on April 8, 2020. |
|
| April 8, 2020 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Forma Securities Corporation Massachusetts Forma Therapeutics, Inc. Delaware |
|
| April 8, 2020 |
FORMA THERAPEUTICS HOLDINGS, INC. 2019 STOCK INCENTIVE PLAN EX-10.1 Exhibit 10.1 FORMA THERAPEUTICS HOLDINGS, INC. 2019 STOCK INCENTIVE PLAN 1. Purpose and Eligibility. The purpose of this 2019 Stock Incentive Plan (the “Plan”) of Forma Therapeutics Holdings, Inc. (the “Company”) is to provide stock options and other equity interests (including restricted stock, restricted stock units and other stock-based interests) in the Company (each an “Award”) to emp |
|
| April 8, 2020 |
BY-LAWS OF FORMA THERAPEUTICS HOLDINGS, INC. A DELAWARE CORPORATION EX-3.3 Exhibit 3.3 BY-LAWS OF FORMA THERAPEUTICS HOLDINGS, INC. A DELAWARE CORPORATION Dated: October 2, 2019 TABLE OF CONTENTS ARTICLE I MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings 1 Section 2. Annual Meeting 1 Section 3. Special Meetings 1 Section 4. Notice of Meetings 2 Section 5. Voting List 2 Section 6. Quorum 2 Section 7. Adjournments 2 Section 8. Action at Meetings 3 Section 9. |
|
| April 8, 2020 |
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.1 Exhibit 4.1 Execution Version THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 18, 2019, by and among Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on Exhibit A hereto, each of which (together with any transferee of Preferred S |
|
| April 8, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORMA THERAPEUTICS HOLDINGS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Forma Therapeutics Holdings, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES |
